Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC

Bintrafusp alfa with chemotherapy was found to have a manageable safety profile and encouraging clinical activity in patients with stage IV NSCLC.

Authors

Sandrine Hiret (ORCID: https://orcid.org/0000-0002-3789-8171)
Yulia Vugmeyster (ORCID: https://orcid.org/0000-0002-6289-2521)
François Ghiringhelli (ORCID: https://orcid.org/0000-0002-5465-8305)
Masashi Sato (ORCID: https://orcid.org/0009-0009-3852-4591)
Firas Badin (ORCID: https://orcid.org/0009-0001-0693-3747)
Surendra Pal Chaudhary (ORCID: https://orcid.org/0000-0003-1541-8314)
Laurent Greillier (ORCID: https://orcid.org/0000-0002-5807-9503)
Rémi Veillon
Christian Diego Rolfo (ORCID: https://orcid.org/0000-0002-7860-8417)
Nicolás Isambert (ORCID: https://orcid.org/0000-0003-3596-2114)
Astrid Paulus

University of Liège (BE)
Merck KGaA, Darmstadt (Germany) (DE)
Aix-Marseille Université (FR)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Centre Hospitalier Universitaire de Bordeaux (FR)
Assistance Publique Hôpitaux de Marseille (FR)
Central Baptist Hospital (US)
Centre Georges François Leclerc (FR)
Ono Pharmaceutical (United States) (US)
Institut de Cancérologie de l'Ouest (FR)
Centre Inria d'Université Côte d'Azur (FR)
Centre Hospitalier Universitaire de Poitiers (FR)
Centre Hospitalier Universitaire de Liège (BE)
Icahn School of Medicine at Mount Sinai (US)